Shares of Quest PharmaTech Inc. (CVE:QPT – Get Free Report) reached a new 52-week low on Thursday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2250 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Trading Down 20.0%
The stock has a market capitalization of C$3.38 million, a PE ratio of 0.67 and a beta of 0.00. The firm has a 50-day moving average price of C$0.03 and a 200-day moving average price of C$0.03. The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Further Reading
- Five stocks we like better than Quest PharmaTech
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
- MarketBeat Week in Review – 07/13- 07/17
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
